DiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of Directors

Falciani’s healthcare leadership and medtech commercialization expertise will help guide DiscGenics as it advances its regenerative spine therapy platform.

SALT LAKE CITY, UT / ZM NEWSWIRE / June 25, 2026 / DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the appointment of Chad Falciani to its Board of Directors.

Mr. Falciani is a proven healthcare entrepreneur, investor, and business leader and is the Founder and Chairman of Curiteva, a high-growth medical technology company focused on transformative biomaterials, in-house manufacturing, and an innovative platform of orthopedic implants. Over the course of his career, Mr. Falciani has developed deep expertise across a diverse range of industries, including banking, finance, medtech, biologics, and aerospace. Mr. Falciani has served on numerous corporate and advisory boards, and has led through mergers & acquisitions, capital formation, operational expansion, and commercialization efforts.

Mr. Falciani joins the DiscGenics Board as the Company advances IDCT (rebonuputemcel), its investigational, allogeneic, injectable disc cell therapy, through late-stage clinical development and continues preparing for future commercialization.

“I have worked closely with Chad and have seen firsthand why so many organizations seek his counsel,” said Kevin Foley, MD, Chief Medical Officer & member of the DiscGenics Board of Directors. “He has an exceptional ability to understand where a company is today, identify where it needs to go, and help build the strategic path to get there. As DiscGenics advances from years of scientific and clinical progress toward broader commercialization readiness, Chad’s experience scaling organizations, strengthening operations, and guiding long-term strategy will be invaluable.”

“We are pleased to welcome Chad to the DiscGenics Board at an important stage in the Company’s evolution,” said Flagg Flanagan, Chairman and Chief Executive Officer of DiscGenics. “His experience across manufacturing, quality systems, finance, and strategic planning aligns closely with the capabilities DiscGenics is building as we advance IDCT through late-stage development and prepare for the next phase of growth. We look forward to benefiting from his leadership, perspective, and proven ability to turn vision into execution.”

About DiscGenics
DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain.

DiscGenics has developed a proprietary, commercial-scale, in-house allogeneic cell manufacturing process and built and qualified a cGMP facility at its Salt Lake City, Utah headquarters.

For more information, visit discgenics.com

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the therapeutic potential, regulatory status, commercialization timing, market opportunity, post-marketing commitments, and future development of IDCT. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including regulatory developments, clinical outcomes, manufacturing readiness, reimbursement decisions, commercialization execution, and other factors. DiscGenics undertakes no obligation to update these statements except as required by law.

Media Contact:
Bethany Perez
Executive Assistant, DiscGenics
Phone: (615) 801-4010
Email: bethany@discgenics.com

SOURCE: DiscGenics

Publication Partner: ZM Newswire – Powered By Zeest Media